Federal Byetta, Victoza, Januvia Lawsuits Consolidated in California, Rottenstein Law Group LLP Reports

August 29, 2013

The firm is currently evaluating Byetta, Victoza and Januvia lawsuits for those who have suffered from the drugs’ alleged potentially serious side effects, such as pancreatic cancer and thyroid cancer.

(PRWEB) August 29, 2013

Byetta, Januvia and Victoza lawsuits were consolidated on Aug. 28 in federal district court in California, according to court documents. The Rottenstein Law Group LLP, a diabetes drug law firm, explains what this means for those looking to file lawsuits over the drugs.

The U.S. Judicial Panel on Multidistrict Litigation ordered the consolidation of 53 nationwide lawsuits involving some diabetes drugs, including Byetta, Januvia and Victoza, all of which are allegedly linked to pancreatic cancer, according to court documents (In RE: Incretin Mimetics Products Liability Litigation; MDL-2452, U.S. District Court for the Southern District of California).

The three drugs are designed to treat type-2 diabetes. The plaintiffs in the cases for the drugs all have a common cause for filing a lawsuit, alleging that they suffered the same potentially dangerous side effects, according to court documents.

“The multidistrict litigation is designed specifically to speed up pretrial proceedings such as discovery—the gathering of evidence,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “What this means for plaintiffs is that their lawsuits have the potential to go to trial faster with the potential for a faster outcome in their favor.”

Rottenstein pointed out, though, that the damages award would not be shared with multiple plaintiffs.

“Each plaintiff who files his or her own lawsuit is still able to have his or her own trial and his or her own damages award,” Rottenstein said. “People often confused these federal consolidations with class actions, but they are fundamentally different types of litigation.”

A March 2013 announcement* by the U.S. Food and Drug Administration said that the three drugs caused inflammation of the pancreas and pre-cancerous changes to the cells of the pancreas. Bristol-Myers Squibb subsidiary Amylin Pharmaceuticals makes Byetta, Merck Januvia and Novo Nordisk Victoza. Byetta and Januvia were also found to potentially increase the risk of thyroid cancer, according to the FDA.**

The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged adverse side effects of Byetta, Januvia and Victoza to visit its FAQ pages for each drug for quick answers to their questions about the drugs, their side effects and lawsuits. If there are additional questions, those looking for more information can use the contact form to get in touch with an attorney.




The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)


The Rottenstein Law Group LLP

Rochelle Rottenstein, Esq.

321 W. 44th Street

# 804

New York NY 10036

(212) 933-9500 (office phone)

(212) 933-9980 (facsimile)

rochelle (at) rotlaw (dot) com


For the original version on PRWeb visit: http://www.prweb.com/releases/byetta-lawsuits/pancreatic-cancer/prweb11075552.htm

Source: prweb

comments powered by Disqus